NASDAQ:ACOR
Acorda Therapeutics Stock News
$11.91
-0.190 (-1.57%)
At Close: Mar 27, 2024
The Daily Biotech Pulse: Bristol Myers, BridgeBio Ink Oncology Pact, FDA Nod For Lava Therapeutics Blood Cancer Study And More
12:42pm, Thursday, 12'th May 2022 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours:
Stocks In Focus
BridgeBio Inks Licensing Pact With Bristol Myers For SHP2 Inhibitor In Oncology
BridgeBio Pharma Inc
Acorda Therapeutics, Inc. (ACOR) CEO Ron Cohen on Q1 2022 Results - Earnings Call Transcript
08:22pm, Wednesday, 11'th May 2022
Start Time: 16:30 January 1, 0000 5:02 PM ET Acorda Therapeutics, Inc. (NASDAQ:ACOR ) Q1 2022 Earnings Conference Call May 11, 2022, 16:30 PM ET Company Participants Ron Cohen - Founder, President and
Acorda Therapeutics, Inc. (ACOR) CEO Ron Cohen on Q4 2021 Results - Earnings Call Transcript
02:21am, Thursday, 10'th Mar 2022 Seeking AlphaAcorda Therapeutics rises postmarket after quarterly loss narrows 75%
10:16pm, Wednesday, 09'th Mar 2022 Seeking Alpha
Acorda Therapeutics (ACOR) is up 2% in after-hours trading following the biotech Q4 2021 and full-year earnings.
Acorda Therapeutics, Inc. (ACOR) CEO Ron Cohen on Q4 2021 Results - Earnings Call Transcript
09:21pm, Wednesday, 09'th Mar 2022
Acorda Therapeutics, Inc. (ACOR) CEO Ron Cohen on Q4 2021 Results - Earnings Call Transcript
Acorda Therapeutics Non-GAAP EPS of -$0.67, revenue of $36.07M beats by $5.06M
09:03pm, Wednesday, 09'th Mar 2022 Seeking Alpha
Acorda Therapeutics press release (NASDAQ:ACOR): Q4 Non-GAAP EPS of -$0.67.Revenue of $36.07M (-5.5% Y/Y) beats by $5.06M.
Acorda Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results
09:01pm, Wednesday, 09'th Mar 2022 Business Wire
ARDSLEY, N.Y.--(BUSINESS WIRE)--Acorda Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results
Acorda Therapeutics Q4 Earnings Preview
10:35pm, Tuesday, 08'th Mar 2022 Seeking Alpha
Acorda Therapeutics (NASDAQ:ACOR) is scheduled to announce Q4 earnings results on Wednesday, March 9th, after market close.The consensus EPS Estimate is -$1.11 (compared to -$2.50 in…
Acorda Fourth Quarter/Year End 2021 Update: Webcast/Conference Call Scheduled for March 9, 2022
10:00pm, Thursday, 24'th Feb 2022 Business Wire
Acorda Fourth Quarter/Year End 2021 Update: Webcast/Conference Call Scheduled for March 9, 2022
Acorda Fourth Quarter/Year End 2021 Update: Webcast/Conference Call Scheduled for March 9, 2022
05:00pm, Thursday, 24'th Feb 2022
ARDSLEY, N.Y.--(BUSINESS WIRE)--Acorda Fourth Quarter/Year End 2021 Update: Webcast/Conference Call Scheduled for March 9, 2022
Acorda Therapeutics Inc Shares Close in on 52-Week Low - Market Mover
02:44am, Sunday, 16'th Jan 2022 Kwhen Finance
Acorda Therapeutics Inc (ACOR) shares closed today at 1.4% above its 52 week low of $2.13, giving the company a market cap of $20M. The stock is currently down 9.6% year-to-date, down 66.1% over the past 12 months, and down 98.3% over the past five years. This week, the Dow Jones Industrial Average fell 0.9%, and the S&P 500 fell 0.3%. Trading Activity Trading volume this week was 52.5% lower than the 20-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 1.0. Technical Indicators The Relative Strength Index (RSI) on the stock was between 30 and 70.MACD, a trend-following momentum indicator, indicates a downward trend.The stock closed above its Bollinger band, indicating it may be overbought.
Market Comparative Performance The company's share price is the same as the S&P 500 Index , lags it on a 1-year basis, and lags it on a 5-year basis The company's share price is the same as the Dow Jones Industrial Average , lags it on a 1-year basis, and lags it on a 5-year basis The company share price is the same as the performance of its peers in the Health Care industry sector , lags it on a 1-year basis, and lags it on a 5 year basis Per Group Comparative Performance The company's stock price performance year-to-date beats the peer average by -41.2% The company's stock price performance over the past 12 months lags the peer average by 373.7%
This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to [email protected]. © 2020 Kwhen Inc.
Acorda Therapeutics Inc Shares Close in on 52-Week Low - Market Mover
01:08am, Monday, 10'th Jan 2022 Kwhen Finance
Acorda Therapeutics Inc (ACOR) shares closed today at 1.8% above its 52 week low of $2.25, giving the company a market cap of $21M. The stock is currently down 4.2% year-to-date, down 44.3% over the past 12 months, and down 98.2% over the past five years. This week, the Dow Jones Industrial Average fell 0.3%, and the S&P 500 fell 1.9%. Trading Activity Trading volume this week was 41.8% lower than the 20-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 1.1. Technical Indicators The Relative Strength Index (RSI) on the stock was under 30, indicating it may be underbought.MACD, a trend-following momentum indicator, indicates a downward trend.The stock closed above its Bollinger band, indicating it may be overbought.
Market Comparative Performance The company's share price is the same as the S&P 500 Index , lags it on a 1-year basis, and lags it on a 5-year basis The company's share price is the same as the Dow Jones Industrial Average , lags it on a 1-year basis, and lags it on a 5-year basis The company share price is the same as the performance of its peers in the Health Care industry sector , lags it on a 1-year basis, and lags it on a 5 year basis Per Group Comparative Performance The company's stock price performance year-to-date beats the peer average by -62.2% The company's stock price performance over the past 12 months lags the peer average by 605.6%
This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to [email protected]. © 2020 Kwhen Inc.
Acorda Therapeutics to Present at the H.C. Wainwright BIOCONNECT Virtual Conference
07:11am, Tuesday, 04'th Jan 2022
ARDSLEY, N.Y.--(BUSINESS WIRE)--Acorda Therapeutics to Present at the H.C. Wainwright BIOCONNECT Virtual Conference
Acorda Therapeutics Inc Shares Close in on 52-Week Low - Market Mover
09:41am, Sunday, 26'th Dec 2021 Kwhen Finance
Acorda Therapeutics Inc (ACOR) shares closed today at 1.7% above its 52 week low of $2.34, giving the company a market cap of $22M. The stock is currently down 42.5% year-to-date, down 45.2% over the past 12 months, and down 97.8% over the past five years. This week, the Dow Jones Industrial Average rose 1.6%, and the S&P 500 rose 2.3%. Trading Activity Trading volume this week was 69.3% lower than the 20-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 1.1. Technical Indicators The Relative Strength Index (RSI) on the stock was under 30, indicating it may be underbought.MACD, a trend-following momentum indicator, indicates an upward trend.The stock closed below its Bollinger band, indicating it may be oversold.
Market Comparative Performance The company's share price is the same as the S&P 500 Index , lags it on a 1-year basis, and lags it on a 5-year basis The company's share price is the same as the Dow Jones Industrial Average , lags it on a 1-year basis, and lags it on a 5-year basis The company share price is the same as the performance of its peers in the Health Care industry sector , lags it on a 1-year basis, and lags it on a 5 year basis Per Group Comparative Performance The company's stock price performance year-to-date lags the peer average by 6228.0% The company's stock price performance over the past 12 months lags the peer average by 896.7%
This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to [email protected]. © 2020 Kwhen Inc.
Multiple Sclerosis Market to Witness Notable Growth by 2027 Covid-19 Analysis | Abbvie, Acorda Therapeutics
10:19am, Wednesday, 15'th Dec 2021 OpenPR
This Multiple Sclerosis market report describes the factors that contribute to the sector''s development as well as market channels. When taken in order, this Multiple Sclerosis market report starts with an introduction to the commercial chain structure and then moves